$IOVA
IOVANCE BIOTHERAPEUTICS, INC.

2021 Q4 Form 10-Q Financial Statement

#000155837021014670 Filed on November 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $23.85M $20.89M $16.08M
YoY Change 48.31% 31.2% 47.93%
% of Gross Profit
Research & Development $75.62M $65.36M $52.45M
YoY Change 44.17% 51.81% -3.3%
% of Gross Profit
Depreciation & Amortization $1.345M $1.000M $320.0K
YoY Change 320.31% 233.33% 10.34%
% of Gross Profit
Operating Expenses $99.47M $86.24M $68.53M
YoY Change 45.14% 46.26% 5.25%
Operating Profit -$86.24M
YoY Change 46.26%
Interest Expense $135.0K $120.0K $140.0K
YoY Change -3.57% -70.0% -90.91%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$99.33M -$86.12M -$68.40M
YoY Change 45.22% 47.04% 7.6%
Income Tax
% Of Pretax Income
Net Earnings -$99.33M -$86.12M -$68.40M
YoY Change 45.23% 47.04% 7.6%
Net Earnings / Revenue
Basic Earnings Per Share -$0.55
Diluted Earnings Per Share -$632.8K -$0.55 -$494.6K
COMMON SHARES
Basic Shares Outstanding 156.9M 155.5K 146.7M
Diluted Shares Outstanding 155.5K

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $504.4M $576.4M $629.4M
YoY Change -19.86% -19.28% 104.96%
Cash & Equivalents $78.23M $58.59M $67.33M
Short-Term Investments $426.2M $517.9M $562.1M
Other Short-Term Assets $3.546M $6.577M $6.700M
YoY Change -47.07% -30.03% -28.72%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $508.0M $583.0M $636.1M
YoY Change -20.15% -19.43% 100.98%
LONG-TERM ASSETS
Property, Plant & Equipment $100.9M $88.03M $59.16M
YoY Change 70.62% 125.08% 593.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $91.59M $78.25M
YoY Change
Other Assets $1.784M $1.011M $12.92M
YoY Change -86.19% -70.13% 271.1%
Total Long-Term Assets $269.4M $245.8M $132.4M
YoY Change 103.52% 318.71% 369.99%
TOTAL ASSETS
Total Short-Term Assets $508.0M $583.0M $636.1M
Total Long-Term Assets $269.4M $245.8M $132.4M
Total Assets $777.3M $828.8M $768.5M
YoY Change 1.15% 5.95% 122.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $27.38M $12.18M $13.51M
YoY Change 102.6% -50.87% -13.19%
Accrued Expenses $56.77M $45.97M $35.07M
YoY Change 61.85% 41.88% 115.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $89.20M $64.77M $54.87M
YoY Change 62.56% 0.58% 40.39%
LONG-TERM LIABILITIES
Long-Term Debt $1.000M $1.000M $0.00
YoY Change
Other Long-Term Liabilities $65.47M $64.73M $11.71M
YoY Change 458.94% 2652.08% 398.04%
Total Long-Term Liabilities $66.47M $65.73M $57.09M
YoY Change 16.44% 984.1% 764.98%
TOTAL LIABILITIES
Total Short-Term Liabilities $89.20M $64.77M $54.87M
Total Long-Term Liabilities $66.47M $65.73M $57.09M
Total Liabilities $155.7M $130.5M $112.0M
YoY Change 39.04% 85.22% 145.07%
SHAREHOLDERS EQUITY
Retained Earnings -$1.172B -$1.073B -$830.2M
YoY Change 41.23% 40.87% 45.49%
Common Stock $7.000K $7.000K $6.000K
YoY Change 16.67% 16.67% 20.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $621.7M $698.3M $656.5M
YoY Change
Total Liabilities & Shareholders Equity $777.3M $828.8M $768.5M
YoY Change 1.15% 5.95% 122.96%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q4
OPERATING ACTIVITIES
Net Income -$99.33M -$86.12M -$68.40M
YoY Change 45.23% 47.04% 7.6%
Depreciation, Depletion And Amortization $1.345M $1.000M $320.0K
YoY Change 320.31% 233.33% 10.34%
Cash From Operating Activities -$53.85M -$57.69M -$62.69M
YoY Change -14.1% 42.42% 16.48%
INVESTING ACTIVITIES
Capital Expenditures -$7.568M -$9.685M -$23.33M
YoY Change -67.56% -45.74% 580.17%
Acquisitions
YoY Change
Other Investing Activities $76.91M $22.43M $82.09M
YoY Change -6.32% -163.89% 171.46%
Cash From Investing Activities $69.34M $12.75M $58.76M
YoY Change 18.0% -124.07% 119.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.150M 20.77M 2.960M
YoY Change 40.2% 1690.69% 41.63%
NET CHANGE
Cash From Operating Activities -53.85M -57.69M -62.69M
Cash From Investing Activities 69.34M 12.75M 58.76M
Cash From Financing Activities 4.150M 20.77M 2.960M
Net Change In Cash 19.64M -24.17M -970.0K
YoY Change -2124.64% -73.81% -96.11%
FREE CASH FLOW
Cash From Operating Activities -$53.85M -$57.69M -$62.69M
Capital Expenditures -$7.568M -$9.685M -$23.33M
Free Cash Flow -$46.28M -$48.01M -$39.36M
YoY Change 17.58% 111.86% -21.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.41
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
155508
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146492
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152221
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
135457
dei Entity Central Index Key
EntityCentralIndexKey
0001425205
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
156702653
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
146874917
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
156702653
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36860
dei Entity Registrant Name
EntityRegistrantName
IOVANCE BIOTHERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
75-3254381
dei Entity Address Address Line1
EntityAddressAddressLine1
999 Skyway Road, Suite 150
dei Entity Address City Or Town
EntityAddressCityOrTown
San Carlos
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94070
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
260-7120
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common stock, par value $0.000041666 per value
dei Trading Symbol
TradingSymbol
IOVA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
156899118
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58590000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67329000
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
517859000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
562108000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6577000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6663000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
583026000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
636100000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
88034000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
59159000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
72423000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
54756000
CY2021Q3 us-gaap Long Term Investments
LongTermInvestments
78247000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
6084000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
5525000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1011000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12918000
CY2021Q3 us-gaap Assets
Assets
828825000
CY2020Q4 us-gaap Assets
Assets
768458000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
12181000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13513000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45969000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
35074000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6616000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6284000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
64766000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
54871000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
64729000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45375000
CY2021Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
1000000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
11714000
CY2021Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
65729000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
57089000
CY2021Q3 us-gaap Liabilities
Liabilities
130495000
CY2020Q4 us-gaap Liabilities
Liabilities
111960000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000041666
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000041666
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
156702653
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
146874917
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
7000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
19000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1771440000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1486662000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1073115000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-830193000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
698330000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
656498000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
828825000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
768458000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
65355000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43050000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
183423000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
149276000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20887000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15916000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
59815000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
44127000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
86242000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
58966000
us-gaap Operating Expenses
OperatingExpenses
243238000
us-gaap Operating Expenses
OperatingExpenses
193403000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-86242000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-58966000
us-gaap Operating Income Loss
OperatingIncomeLoss
-243238000
us-gaap Operating Income Loss
OperatingIncomeLoss
-193403000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
120000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
395000
us-gaap Investment Income Interest
InvestmentIncomeInterest
316000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2219000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-86122000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-58571000
us-gaap Net Income Loss
NetIncomeLoss
-242922000
us-gaap Net Income Loss
NetIncomeLoss
-191184000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.60
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.41
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155508
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146492
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
152221
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
135457
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-86122000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-58571000
us-gaap Net Income Loss
NetIncomeLoss
-242922000
us-gaap Net Income Loss
NetIncomeLoss
-191184000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-38000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-162000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-24000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-65000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-86160000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58733000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-242946000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-191249000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
744413000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19306000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20771000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-38000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-86122000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
698330000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
758309000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10706000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1516000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-162000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
43000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-58571000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
711841000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
656498000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
50661000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
970000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29992000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
203155000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-24000
us-gaap Net Income Loss
NetIncomeLoss
-242922000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
698330000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
298971000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
30655000
us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
-283000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6704000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-65000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
567043000
us-gaap Net Income Loss
NetIncomeLoss
-191184000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
711841000
us-gaap Net Income Loss
NetIncomeLoss
-242922000
us-gaap Net Income Loss
NetIncomeLoss
-191184000
us-gaap Share Based Compensation
ShareBasedCompensation
50661000
us-gaap Share Based Compensation
ShareBasedCompensation
30655000
iova Non Cash Lease Expense
NonCashLeaseExpense
7630000
iova Non Cash Lease Expense
NonCashLeaseExpense
4999000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
5177000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
359000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1766000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
819000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-11993000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-66000
iova Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
25297000
iova Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
4986000
iova Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
19686000
iova Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-593000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-740000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
9168000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2046000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
8255000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-174092000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-142442000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
544454000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
358493000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
583654000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
711643000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
30006000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23456000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-69206000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-376606000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
283000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
30962000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6704000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
203156000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
567043000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
1000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
235118000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
573464000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-8180000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
54416000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72854000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19419000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64674000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73835000
iova Unrealized Gain Loss On Short Term Investments
UnrealizedGainLossOnShortTermInvestments
-24000
iova Unrealized Gain Loss On Short Term Investments
UnrealizedGainLossOnShortTermInvestments
-65000
iova Acquisitions Of Property And Equipment Included In Accounts Payable And Accrued Expense
AcquisitionsOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpense
635000
iova Acquisitions Of Property And Equipment Included In Accounts Payable And Accrued Expense
AcquisitionsOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpense
8061000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
1000
iova Rightofuseassetobtainedinexchangeforoperatingleaseliabilityfromnewleases
Rightofuseassetobtainedinexchangeforoperatingleaseliabilityfromnewleases
17275000
iova Rightofuseassetobtainedinexchangeforoperatingleaseliabilityfromnewleases
Rightofuseassetobtainedinexchangeforoperatingleaseliabilityfromnewleases
4667000
iova Right Of Use Asset Obtained In Exchange For Operating Lease Liability From Lease Modifications
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityFromLeaseModifications
7800000
iova Right Of Use Asset Obtained In Exchange For Operating Lease Liability From Lease Modifications
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityFromLeaseModifications
22000
us-gaap Net Income Loss
NetIncomeLoss
-242900000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-174100000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
203200000
CY2021Q3 iova Cash Cash Equivalents And Short Term Investments And Restricted Cash Total
CashCashEquivalentsAndShortTermInvestmentsAndRestrictedCashTotal
660800000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58600000
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
517900000
CY2021Q3 us-gaap Long Term Investments
LongTermInvestments
78200000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
6100000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
6100000
CY2021Q3 iova Security Deposit For Benefit Of Landlord For Commercial Manufacturing Facility
SecurityDepositForBenefitOfLandlordForCommercialManufacturingFacility
5450000
CY2021Q3 iova Security Deposit For Benefit Of Utilities Service Provider
SecurityDepositForBenefitOfUtilitiesServiceProvider
74685
CY2021Q3 iova Security Deposit For Benefit Of Landlord For New Headquarters Lease
SecurityDepositForBenefitOfLandlordForNewHeadquartersLease
559082
CY2021Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
1000000.0
CY2021Q3 us-gaap Security Deposit
SecurityDeposit
1450000
CY2021Q3 iova Security Deposit For Benefit Of Utilities Service Provider
SecurityDepositForBenefitOfUtilitiesServiceProvider
74685
CY2021Q3 iova Security Deposit For Benefit Of Landlord For New Headquarters Lease
SecurityDepositForBenefitOfLandlordForNewHeadquartersLease
559082
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
6100000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
5500000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58590000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68310000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
6084000
CY2020Q3 us-gaap Restricted Cash
RestrictedCash
5525000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64674000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73835000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16673579
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16447000
CY2021Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
638681000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
611828000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
50000
CY2021Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
42575000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
49720000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
562108000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
596106000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
562108000
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
596113000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
517859000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
78247000
CY2021Q3 iova Cash Equivalents And Investments
CashEquivalentsAndInvestments
638681000
CY2020Q4 iova Cash Equivalents And Investments
CashEquivalentsAndInvestments
611828000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:27.35pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the assumptions made in valuing stock instruments issued for services and used in measuring operating right-of-use assets and operating lease liabilities, accounting for potential liabilities, capitalization of internal-use software development costs, and the valuation allowance associated with the Company’s deferred tax assets.</span></p>
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
54000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7344000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
78247000
CY2021Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
42575000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
49720000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
517859000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
562108000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
596106000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
562108000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
61000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
596106000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
562089000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5578000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
31000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
562108000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
517835000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
517859000
CY2021Q3 iova Available For Sale Debt Securities Maturity Rolling After One Through Two Years Amortized Cost
AvailableForSaleDebtSecuritiesMaturityRollingAfterOneThroughTwoYearsAmortizedCost
78278000
CY2021Q3 iova Available For Sale Debt Securities Maturity Rolling After One Through Two Years Fair Value
AvailableForSaleDebtSecuritiesMaturityRollingAfterOneThroughTwoYearsFairValue
78247000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
596113000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
596106000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
95378000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
64737000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
88034000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
59159000
CY2021Q3 us-gaap Depreciation
Depreciation
1000000.0
CY2020Q3 us-gaap Depreciation
Depreciation
300000
us-gaap Depreciation
Depreciation
1800000
us-gaap Depreciation
Depreciation
800000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
156702653
CY2021Q3 iova Clinical Related Expenses Current
ClinicalRelatedExpensesCurrent
12577000
CY2020Q4 iova Clinical Related Expenses Current
ClinicalRelatedExpensesCurrent
15661000
CY2021Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
15167000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
9032000
CY2021Q3 iova Manufacturing Related Expenses Current
ManufacturingRelatedExpensesCurrent
9108000
CY2020Q4 iova Manufacturing Related Expenses Current
ManufacturingRelatedExpensesCurrent
3266000
CY2021Q3 iova Commercial Manufacturing Facility Related Current
CommercialManufacturingFacilityRelatedCurrent
5082000
CY2020Q4 iova Commercial Manufacturing Facility Related Current
CommercialManufacturingFacilityRelatedCurrent
4342000
CY2021Q3 iova Legal And Related Services Current
LegalAndRelatedServicesCurrent
1671000
CY2020Q4 iova Legal And Related Services Current
LegalAndRelatedServicesCurrent
1061000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2364000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1712000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45969000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
35074000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000041666
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
19306000
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
10706000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
50661000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
30655000
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
19306000
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
10706000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
50661000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
30655000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
23.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
16.37
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">NOTE 9. LEGAL PROCEEDINGS </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Derivative Lawsuit.</span> On December 11, 2020, a purported stockholder derivative complaint was filed by plaintiff Leo Shumacher against the Company, as nominal defendant, and <span style="white-space:pre-wrap;">its current directors, as defendants, in the Court of Chancery in the State of Delaware. The complaint alleges breach of fiduciary duty and a claim for unjust enrichment in connection with alleged excessive compensation of certain non-executive directors of the Company </span>and seeks unspecified damages on behalf of the Company<span style="white-space:pre-wrap;">. The defendants intend to vigorously defend against the foregoing complaints. Based on the early stage of the litigation, it is not possible to estimate the amount or range of possible loss that might result from these matters.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.35pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Solomon Capital, LLC.</span> On April 8, 2016, a lawsuit (“the First Solomon Suit”) titled <i style="font-style:italic;">Solomon Capital, LLC, Solomon Capital 401(K) Trust, Solomon Sharbat and Shelhav Raff v. Lion Biotechnologies, Inc.</i> was filed by Solomon Capital, LLC, Solomon Capital 401(k) Trust, Solomon Sharbat and Shelhav Raff (“Solomon Plaintiffs”) against the Company in the Supreme Court of the State of New York, County of New York (index no. 651881/2016). The Solomon Plaintiffs allege that, between June and November 2012, they provided to the Company $0.1 million and that they advanced and paid on behalf of the Company an additional $0.2 million. The complaint further alleges that the Company agreed to (i) provide them with promissory notes totaling $0.2 million, plus interest, (ii) issue a total of 1,110 shares to the Solomon Plaintiffs (after the <span style="-sec-ix-hidden:Hidden_gQiHExW8BUSimNshpLkxkg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">1-for-100</span></span> reverse split of the Company’s common stock effected in March 2013) (the “Equity Claim”), and (iii) allow the Solomon Plaintiffs to convert the foregoing funds into its securities in the next financing of the Company on the same terms offered to other investors, which Solomon Plaintiffs allege, should have given them the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">right to convert their advances and payments into shares of the Company's common stock in the restructuring that took effect in May 2013. Based on the foregoing, the Solomon Plaintiffs allege causes for breach of contract and unjust enrichment and demand judgment against the Company in an unspecified amount exceeding $1.5 million, plus interest. On June 3, 2016, the Company filed an answer and counterclaims in the lawsuits. The Company has asserted counterclaims for fraudulent inducement, fraudulent misrepresentation, fraudulent concealment, breach of fiduciary duty, and breach of contract, alleging principally that the counterclaim defendants misrepresented their qualifications and failed to disclose that Solomon Sharbat was the subject of an investigation by the Financial Industry Regulatory Authority (“FINRA”) that resulted in the loss of his FINRA license. In its counterclaims, the Company is seeking damages in an amount exceeding $0.5 million and an order rescinding any and all agreements that the Solomon Plaintiffs contend entitled them to obtain shares of Company stock. On May 12, 2020, the court granted the Company’s motion for summary judgment limiting the Solomon Plaintiffs’ damages for the Equity Claim to $47,420. The Solomon Plaintiffs filed a notice of appeal of this summary judgment on June 9, 2020. On July 2, 2020, the court granted the Company’s motion to dismiss the First Solomon Suit for want of prosecution. On January 4, 2021, the court granted the Solomon Plaintiffs motion for reconsideration, and reinstituted the case. On January 15, 2021, the Company filed a notice of appeal of the court’s grant of the Solomon Plaintiffs motion for reconsideration. On May 11, 2021, the Appellate Division upheld the court’s grant of the Solomon Plaintiffs’ motion for reconsideration of the dismissal of the First Solomon Suit for want of prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.35pt;margin:0pt 0pt 10pt 0pt;">On September 27, 2019, the Solomon Plaintiffs filed a new lawsuit (through new legal counsel) (“the Second Solomon Suit”) titled <i style="font-style:italic;">Solomon Capital, LLC, Solomon Capital 401(K) Trust, Solomon Sharbat and Shelhav Raff v. Iovance Biotherapeutics, Inc., f/k/a/ Lion Biotechnologies Inc. f/k/a/ Genesis Biopharma Inc., and Manish Singh</i> in the Supreme Court of the State of New York, County of New York (index no. 655668/2019). In the Second Solomon Suit, the Solomon Plaintiffs allege that they are third party beneficiaries of a “finder’s fee agreement” that prior management entered into with a third party unlicensed entity in 2012 in connection with seeking financing, that an agreement or understanding existed between the Company and the plaintiffs that the plaintiffs would be paid fees and commissions (in cash and stock) if they obtained financing for the Company, and that they directly and indirectly introduced investors to the Company who invested in the Company, or were willing to invest in the Company. Finally, the Solomon Plaintiffs allege that they were promised a license to use the Company’s technology in Israel. The plaintiffs claim that the Company breached the foregoing understandings, promises and agreements and, as a result, they are entitled to certain damages. The Solomon Plaintiffs also allege that Manish Singh, the Company’s former Chief Executive Officer, committed fraud and took shares belonging to them. On February 18, 2020, the Company filed a removal petition and removed the Second Solomon Suit to the U.S. District Court for the Southern District of New York, where the case has been assigned case no. 1:20-cv-1391. On May 22, 2020, the Company moved to dismiss the Second Solomon Suit for lack of personal jurisdiction. On March 26, 2021, the Court denied the Company’s motion to dismiss for lack of personal jurisdiction. The Company filed a response to the complaint in the Second Solomon Suit on April 30, 2021. On May 26, 2021, the Company and Singh filed motions for judgment on the pleadings with respect to the second and third claims asserted against the Company and all claims asserted against Singh, respectively, in the Second Solomon Suit. On June 25, 2021, the Solomon Plaintiffs filed an opposition brief against the motions for judgment on the pleadings. On July 16, 2021, the Company and Singh filed reply briefs in support of the motions for judgement on the pleadings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.35pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">The Company intends to vigorously defend these complaints and pursue its counterclaims, as applicable. At the current stage of the litigation, in both the First Solomon Suit and the Second Solomon Suit, it is not possible to estimate the amount or range of possible loss that might result from an adverse judgment or a settlement of these matters. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.35pt;margin:0pt;">The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues amounts, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that it believes will result in a probable loss. While there can be no assurances as to the ultimate outcome of any legal proceeding or other loss contingency involving the Company, management does not believe any pending matter will be resolved in a manner that would have a material adverse effect on its financial position, results of operations or cash flows. </p>
CY2021Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12M
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
71345000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
51659000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
72423000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
4053000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
54756000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6616000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6284000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
64729000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45375000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1652000
us-gaap Operating Lease Cost
OperatingLeaseCost
10831000
us-gaap Operating Lease Cost
OperatingLeaseCost
5361000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1484000
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1702000
us-gaap Variable Lease Cost
VariableLeaseCost
3772000
us-gaap Variable Lease Cost
VariableLeaseCost
4333000
CY2021Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
26000
CY2020Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
26000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
101000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
57000
CY2021Q3 us-gaap Lease Cost
LeaseCost
5563000
CY2020Q3 us-gaap Lease Cost
LeaseCost
3380000
us-gaap Lease Cost
LeaseCost
14704000
us-gaap Lease Cost
LeaseCost
9751000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
3605000
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1893000
us-gaap Operating Lease Payments
OperatingLeasePayments
8439000
us-gaap Operating Lease Payments
OperatingLeasePayments
5995000
CY2021Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
16999000
CY2020Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4667000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
17617000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4667000
CY2021Q3 iova Increase Decrease In Right Of Use Assets From Lease Modifications
IncreaseDecreaseInRightOfUseAssetsFromLeaseModifications
5853000
CY2020Q3 iova Increase Decrease In Right Of Use Assets From Lease Modifications
IncreaseDecreaseInRightOfUseAssetsFromLeaseModifications
206000
iova Increase Decrease In Right Of Use Assets From Lease Modifications
IncreaseDecreaseInRightOfUseAssetsFromLeaseModifications
7796000
iova Increase Decrease In Right Of Use Assets From Lease Modifications
IncreaseDecreaseInRightOfUseAssetsFromLeaseModifications
534000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P15Y3M
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M15D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.072
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3692000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
9492000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
8006000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8206000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8107000
CY2021Q3 iova Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
99931000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
137434000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
66089000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
71345000
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
The granted stock options vest in 12 quarterly installments (with 1/12th of the option shares having vested on the date of grant).
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000

Files In Submission

Name View Source Status
0001558370-21-014670-index-headers.html Edgar Link pending
0001558370-21-014670-index.html Edgar Link pending
0001558370-21-014670.txt Edgar Link pending
0001558370-21-014670-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
iova-20210930.xsd Edgar Link pending
iova-20210930x10q.htm Edgar Link pending
iova-20210930x10q001.jpg Edgar Link pending
iova-20210930x10q_htm.xml Edgar Link completed
iova-20210930xex31d1.htm Edgar Link pending
iova-20210930xex31d2.htm Edgar Link pending
iova-20210930xex32d1.htm Edgar Link pending
iova-20210930xex32d2.htm Edgar Link pending
iova-20210930_cal.xml Edgar Link unprocessable
iova-20210930_def.xml Edgar Link unprocessable
iova-20210930_lab.xml Edgar Link unprocessable
iova-20210930_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending